Aprepitant Oral Powder for Suspension — FDA Drug Shortage
The FDA lists a drug shortage record for Aprepitant Oral Powder for Suspension from Merck Sharp & Dohme LLC with status To Be Discontinued. The shortage was first posted on Apr 8, 2026.
Shortage details
- Status
- To Be Discontinued
- Company
- Merck Sharp & Dohme LLC
- Package NDC
- 0006-3066-03
- Presentation
- Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03)
- Initial Posting
- Apr 8, 2026